Brought to you by 
Forty Seven enters trial collaborations with Merck KGAA and Genentech
Jan 2018
Executive Summary
Forty Seven Inc. entered into trial collaborations with Merck KGAA and Genentech Inc. to evaluate its own antibody Hu5F9G4 as a potential combination therapy for ovarian and bladder cancers and leukemia.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Forty Seven enters trial collaborations with Merck KGAA and Genentech
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice